Macitentan for the treatment of pulmonary arterial hypertension

التفاصيل البيبلوغرافية
العنوان: Macitentan for the treatment of pulmonary arterial hypertension
المؤلفون: Hilary M. DuBrock, Richard N. Channick
المصدر: Expert Review of Respiratory Medicine. 8:393-399
بيانات النشر: Informa UK Limited, 2014.
سنة النشر: 2014
مصطلحات موضوعية: Endothelin Receptor Antagonists, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Hypertension, Pulmonary, Pharmacology, chemistry.chemical_compound, In vivo, Oral administration, Internal medicine, Humans, Immunology and Allergy, Medicine, Antihypertensive Agents, Macitentan, Sulfonamides, business.industry, Endothelin receptor antagonist, Significant difference, Public Health, Environmental and Occupational Health, medicine.disease, Pulmonary hypertension, Clinical trial, Pyrimidines, Treatment Outcome, chemistry, Cardiology, business, Endothelin receptor
الوصف: Macitentan is a novel dual endothelin receptor antagonist recently approved for the treatment of symptomatic pulmonary arterial hypertension (PAH). Compared to other endothelin receptor antagonists, in vitro and in vivo studies have demonstrated that macitentan has improved tissue targeting, a longer duration of action and an improved safety profile. Macitentan is available as a once daily oral medication and has been well tolerated in clinical trials. The recently published Study with an Endothelin Receptor Antagonist in PAH to Improve cliNical Outcomes (SERAPHIN), which was the first event-driven trial ever done in PAH, also demonstrated the benefit of macitentan on reducing the likelihood of a composite endpoint of morbidity and mortality events without a significant difference in mortality.
تدمد: 1747-6356
1747-6348
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49d7331bffe8bcc266618ee09f064b8dTest
https://doi.org/10.1586/17476348.2014.937708Test
رقم الانضمام: edsair.doi.dedup.....49d7331bffe8bcc266618ee09f064b8d
قاعدة البيانات: OpenAIRE